Replication Data for: COVID-19 vaccine booster dose fails to enhance immune response to Omicron variant in reinfected healthcare workers

Resumen

A prospective cohort study was designed to assess durability and level of humoral response of 678 healthcare workers fully vaccinated against COVID-19. They were categorized based on their primary vaccination regimen: two doses of mRNA-1273, BNT162b2, ChAdOx1, a combination of ChAdOx1/BNT162b2, or a single dose of ChAdOx1. Blood samples were collected at three time points: before the booster dose, 1 and 6 months after. One month after boosting significant Anti-S-RBD differences were found between previously infected and naïve volunteers, and between mRNA-1273 and BNT162b2 booster groups (20,839 vs. 14,495 U/mL, respectively, p=0.01). Considering the initial vaccine schedules, mRNA based vaccines displayed significant higher antibody production and longer persistence among, both, infected and naïve participants. After the booster dose, participants primoinfected with the Omicron variant exhibited higher antibody concentrations than those who experienced reinfection, even after 6 months of follow-up (22,545 and 9,460 U/mL, respectively). Moreover, these groups showed the most pronounced disparity in antibody titers ratios between infected and uninfected individuals, highlighting their different immunogenicity. Therefore, the booster dose failed to enhance immunity in people reinfected with the Omicron variant. Hybrid immunity and mRNA-based vaccine initial schedules showed higher levels and longer persistence of antibodies.